Immunotherapy for Hematologic Malignancies
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: 15 August 2026
Special Issue Editor
Interests: hematological malignancy; clinical trials; drug resistance and drug development
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Hematological malignancies present some unique challenges like disease heterogeneity, drug resistance leading to relapse and persistence of minimal residual disease, and the emergent immunosuppressive microenvironment resulting in sanctuary sites within the bone marrow. The introduction of immunotherapy either in the form of immunomodulators, checkpoint inhibitors, immune cell engagers like bispecific T cell engagers (BiTEs), or Chimeric Antigen Receptor (CAR)-T cell therapy has heralded a new era in combating hematological malignancy.
The present issue will focus on studies trying to delineate the process of emergence of the immunosuppressive environment and the advancements made in immune therapy to overcome this hurdle. The emphasis will be on capturing the different approaches utilized to increase the immune-based tools available to improve patient outcomes in hematological malignancy. Areas of interest will include multitargeted approaches in overcoming immune evasion, tumor vaccination, and preventive measures utilized to decrease toxicity, especially immune-related adverse effects.
Dr. Rajesh Ramakrishnan Nair
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immune evasion
- immunotherapy
- CAR-T cell therapy
- BiTEs
- immunomodulators
- checkpoint
- inhibitors
- bone marrow microenvironment
- refractory/relapsed
- drug resistance
- gene editing
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
